Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.68 |
| ▸ | GAA | P10253 | 3/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | ATM | Q13315 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | NPC1 | O15118 | 2/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | CASP1 | P29466 | 1/20 | 0.55 |
| ▸ | CASP7 | P55210 | 1/20 | 0.55 |
| ▸ | HTR1A | P08908 | 4/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4380692 | 0.99 | TSHR (0.69) | TSHRALDH1A1GAAMAPTATM | |
| SCHEMBL13636228 | 0.89 | GAA (0.57) | TSHRALDH1A1GAAMAPTATM | |
| SCHEMBL13779939 | 0.83 | ALDH1A1 (0.79) | TSHRALDH1A1GAAMAPTATM | |
| SCHEMBL4381097 | 0.77 | ALDH1A1 (0.69) | TSHRALDH1A1GAAMAPTATM | |
| SCHEMBL4379269 | 0.77 | ALDH1A1 (0.73) | TSHRALDH1A1GAAMAPTATM | |
| SCHEMBL4386342 | 0.76 | ALDH1A1 (0.75) | TSHRALDH1A1GAAMAPTATM | |
| SCHEMBL2829735 | 0.75 | CDYL2 (0.80) | TSHRALDH1A1GAAMAPTMEN1 | |
| SCHEMBL13801421 | 0.73 | MAPT (0.58) | MAPTMEN1KMT2ANPC1LMNA | |
| SCHEMBL13779980 | 0.72 | ALDH1A1 (0.81) | TSHRALDH1A1GAAMEN1KMT2A | |
| SCHEMBL2008321 | 0.71 | MAPK1 (0.75) | TSHRALDH1A1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1421071-B1 | SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS | HIGH POINT PHARMACEUTICALS LLC (US) | 2009-11-18 | — | — | EP | claimed |
| EP-1421071-B1 | SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS | HIGH POINT PHARMACEUTICALS LLC (US) | 2009-11-18 | — | — | EP | disclosed |
| US-20080113968-A1 | Substituted piperazines and diazepanes | NOVO NORDISK A/S (DK) | 2008-05-15 | — | — | US | disclosed |
| US-20080113968-A1 | Substituted piperazines and diazepanes | NOVO NORDISK A/S (DK) | 2008-05-15 | — | — | US | disclosed |
| US-7208497-B2 | Substituted piperazines and diazepanes | NOVO NORDISK A/S (DK) | 2007-04-24 | — | — | US | disclosed |
| US-7208497-B2 | Substituted piperazines and diazepanes | NOVO NORDISK A/S (DK) | 2007-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113968-A1 | Substituted piperazines and diazepanes | HRH3, HRH4, HRH1 | TSHR 621/4885ALDH1A1 1907/4885GAA 2830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.